AOD-9604 — hGH C-terminal fragment lipid-metabolism research

AOD-9604 is one of the more carefully characterised fragments in the human-growth-hormone research literature: a 16-residue C-terminal synthetic peptide whose published pharmacology is concentrated almost entirely on adipocyte lipid metabolism. Its history runs from a Monash University laboratory in the 1990s through a structured preclinical development program and a series of in-vitro and animal-model lipolysis-research studies that establish what the molecule does and, importantly, what remains unresolved about how it does it.

What AOD-9604 actually is

AOD-9604 (Anti-Obesity Drug 9604 was the original development code used by Metabolic Pharmaceuticals; the chemical-research literature uses the AOD-9604 designation directly) is a synthetic peptide corresponding to amino-acid residues 177-191 of the human growth hormone sequence, with a tyrosine residue appended at the N-terminus to facilitate radiolabelling in the original research. The native fragment is 15 residues; the synthetic AOD-9604 with the N-terminal Tyr is 16 residues, with a molecular weight of approximately 1,815 Da. The internal disulphide bridge between the cysteines at positions equivalent to hGH 182 and 189 is preserved.

The fragment was identified through structure-activity work in the Monash University laboratory of Frank Ng and colleagues, who established in the 1990s that the C-terminal end of the hGH molecule retains a distinct pharmacological profile when separated from the full hormone — specifically, the lipid-metabolism activity of the parent hormone is largely retained while the somatogenic and insulin-modulating activities are not. AOD-9604 was synthesised as a defined version of this C-terminal pharmacology.

What the mechanism research shows

The published in-vitro pharmacology converges on three findings:

• Stimulation of adipocyte lipolysis. The Heffernan 2001 paper in Endocrinology documents that AOD-9604 stimulates lipolysis in isolated rodent and human adipocyte preparations, with the magnitude of the lipolytic response comparable to that produced by intact human growth hormone in the same assay system [1]. The effect is dose-dependent and reproducible in independent preparations.
• Inhibition of lipogenesis. The same Heffernan work and adjacent studies reported reduced activity of lipogenic pathways (de novo fatty-acid synthesis) in the treated adipocyte cultures, alongside the lipolytic effect. The combined profile — increased lipolysis plus decreased lipogenesis — is the in-vitro pharmacological signature of the fragment.
• Lipid-metabolism pharmacology without somatogenic activity. The Ng-Bornstein 2003 review consolidates the position that the C-terminal fragment retains the lipid-metabolic profile of hGH without producing the somatogenic effects of the full hormone — specifically, without driving IGF-1 production or affecting insulin-glucose homeostasis at the doses studied [2].

The receptor-pathway question is the most interesting unresolved point in the literature. AOD-9604 does not appear to signal via the canonical growth-hormone receptor (GHR) at the doses that produce the lipid-metabolism effects in vitro — standard GHR antagonists do not block the lipolytic response in the published preclinical work. The Stier 2013 preclinical pharmacology review documents the receptor-pathway evidence and the alternative-pathway candidates considered [3].

Honest take: the in-vitro adipocyte lipolysis pharmacology of AOD-9604 is reasonably well-replicated. The receptor through which it acts is still not definitively identified in peer-reviewed work — an unusual and interesting situation for a peptide that has been in research circulation for over two decades.

The development history

Metabolic Pharmaceuticals advanced AOD-9604 through a structured preclinical program in the late 1990s and early 2000s, including a series of company-sponsored clinical-pharmacology studies. The molecule received GRAS (Generally Recognized As Safe) status from a US ingredient-regulatory perspective for non-pharmaceutical use, which is what allowed its subsequent appearance in research-supply and adjacent markets — but GRAS classification is a food-ingredient regulatory status, not a medicinal-product approval, and AOD-9604 has never been approved as a medicine by the FDA, EMA, or any equivalent regulator.

From a research-grade-supply standpoint, the development history is relevant context for two reasons. First, the in-vitro pharmacology was characterised by the original developer to a higher standard than is typical for the research-peptide category. Second, the absence of any clinical-product approval means that all clinical claims about the compound are extrapolations from the in-vitro and animal-model data, not conclusions from human RCTs.

The UAE research-supply landscape

AOD-9604 is supplied in the UAE as a lyophilised powder, most commonly 5 mg per vial. The disulphide-linked structure makes the synthesis slightly more demanding than equivalent-length linear peptides, so research-supply purity-control practice varies meaningfully across vendors. The compound is reasonably stable in dry form at -20°C and is typically rated for 28 days at 2-8°C after reconstitution in bacteriostatic water.

Open questions

The questions the published literature has not yet answered:

• Receptor identification. The standard GHR is apparently not the signalling target for the AOD-9604 lipid-metabolism effects; the alternative pathway has been hypothesised but not definitively characterised.
• Human pharmacokinetics. The half-life, distribution, and metabolism in humans have been investigated in company-sponsored work but the public peer-reviewed pharmacokinetic record is thin.
• In-vivo translation. The robust in-vitro adipocyte lipolysis findings have a more variable record when translated to in-vivo animal models — the lipid-metabolism endpoints reported in cell-culture do not always reproduce at equivalent magnitudes in whole-animal preparations.
• Long-term safety. Multi-year administration data does not exist in the published literature. The GRAS classification is based on short-term studies and a specific regulatory pathway, not on long-term clinical follow-up.

Further reading

Peer-reviewed citations used inline:

• [1] Heffernan, Summers, Thorburn et al. — Endocrinology 2001. In-vitro adipocyte lipolysis pharmacology of the hGH C-terminal fragment.
• [2] Ng, Bornstein et al. — 2003 review. Consolidated review of the hGH C-terminal fragment pharmacology and the lipid-metabolism-without-somatogenic-activity profile.
• [3] Stier et al. — preclinical pharmacology review 2013. Review of the receptor-pathway evidence and the alternative-pathway candidates.

Last reviewed 26 May 2026. Wellness Labs supplies AOD-9604 as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.